Safe blood has become safer and more plentiful at the global level, yet whether a patient receives a transfusion still depends heavily on where they live and how strong their health system is. The latest World Health Organization data frame blood safety not only as a technical success story but also as a mirror of persistent structural inequities in health governance and financing.
Progress Built on Voluntary Donors
The new WHO analysis shows that global blood collections rose by nearly 19 percent between 2013 and 2023, reaching an estimated 120 million donations in 2023. More than 85 percent of these donations now come from voluntary unpaid donors, which WHO describes as the cornerstone of safe and sustainable blood supplies. This pattern suggests that long term investment in donor recruitment, awareness campaigns and regulatory safeguards has begun to pay off in many countries.
WHO highlights that voluntary unpaid donation is strongly associated with lower risk of transfusion transmitted infections compared to family replacement or paid donation, because donors are regularly screened and more likely to give repeatedly under standardized conditions. These gains matter across a wide range of clinical settings from obstetric emergencies and trauma care to treatment of haemoglobin disorders and cancers. When WHO Director General Tedros Adhanom Ghebreyesus notes that no one should die because safe blood is unavailable when it is needed, he links technical advances in blood services to a wider human rights framing of access to essential health products.
Geography Still Determines Survival Chances
Despite aggregate progress, the report confirms that access remains deeply unequal, especially between higher income and lower income states. High income countries represent about 15 percent of the global population but collect 36 percent of all blood donations, highlighting a persistent skew in supply relative to need. Blood donation rates range from 0.4 to 53 donations per 1000 people, and 24 countries report fewer than 5 donations per 1000 population, a level that WHO associates with difficulty in providing timely transfusions for many patients.
Patterns of donation also differ sharply by income level. While voluntary unpaid donors account for 98.4 percent of donations in high income countries, the share drops to 63.4 percent in low income countries, where systems rely more heavily on family and replacement donors. In practice, this means that women facing life threatening bleeding in childbirth, children with severe anaemia, people with sickle cell disease and trauma victims in lower income settings are more exposed to shortages, delays or less consistently safe blood. The gap is not only about volumes but also about reliability, with weaker logistics, storage and screening capacity in many constrained health systems.
Governance and Financing as Structural Fault Lines
The WHO findings emphasize that safe blood depends as much on governance and financing as on clinical technology. Nearly one third of countries still lack specific legislation dedicated to ensuring the safety and quality of blood and blood products, which undermines standard setting along the whole chain from collection to transfusion. Only 64 percent of countries report regular inspection systems for blood services, 62 percent report licensing systems, and just 40 percent indicate that at least some blood transfusion services are accredited, exposing gaps in quality assurance.
Financing arrangements remain a critical vulnerability. More than one in seven countries report having neither dedicated government budget allocations nor cost recovery mechanisms for blood services, raising doubts about the sustainability of their national blood supply. Without predictable funding, laboratories struggle to maintain screening reagents, recruit and retain trained staff or invest in cold chain infrastructure, which in turn weakens public trust and discourages regular donation. These structural problems explain why progress can stall or reverse in the face of shocks such as pandemics, economic crises or conflict.
Policy Implications for Universal Health Coverage
The report implicitly positions blood safety as a test case for broader universal health coverage commitments. WHO is urging governments and partners to strengthen governance and regulation, secure sustainable financing, expand quality assurance programs, improve clinical use through patient blood management and reinforce surveillance systems. These priorities align with an updated WHO action framework for 2026 to 2030 that seeks universal access to safe, effective and quality assured blood products as a core component of resilient health systems.
For lower and middle income countries, the implications are twofold. First, shifting towards nationally coordinated, centrally regulated blood services with strong oversight can reduce fragmentation and inequity within countries. Second, integrating blood services into broader health financing reforms, rather than treating them as a stand alone technical program, can stabilize funding and support long term capacity building. International partners also have a role in supporting technology transfer, plasma fractionation capacity and regional collaboration, especially where demand for plasma derived medicinal products is rising faster than domestic collection systems can adapt.
A Final Note
The latest WHO blood safety report combines an optimistic narrative of rising voluntary donation and safer supplies with a stark reminder that geography, legislation and budgets still shape who receives life saving transfusions. Treating blood as an essential health product within universal health coverage agendas will be key to transforming technical progress into genuinely equitable access for patients in all settings.
